Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Interest Income
Income earned on cash, deposits, and investments held by the company.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income growth accelerates
Q2 FY2026 interest income of $3.95M rose 45.4% year over year, ahead of the +35.1% change in trailing-twelve-month interest income. Sequentially, it rose 15.7% from the prior quarter. Over 3 fiscal years it compounded at +110.3% a year.
Context
- Interest income amounted to 1.7% of revenue in FY2025, down 0.5 pp from a year earlier.
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.4% holds above the trailing-twelve-month pace of +35.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 11.65M USD
- Year-over-year change
- +23.1%
- 4-year CAGR
- +231.0%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.65M | +23.1% |
| FY2024 | 2024-12-31 | 9.46M | +10.8% |
| FY2023 | 2023-12-31 | 8.54M | +581.9% |
| FY2022 | 2022-12-31 | 1.25M | +1191.8% |
| FY2021 | 2021-12-31 | 97K | — |
Interest Income vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 interest income of $13.22M is the 6th highest of the 10 companies compared; the peer median is $18.56M.
- Its year-over-year change of +35.1% is the 4th highest of 10, against a peer median of -8.1%.
- Interest income amounts to 1.6% of revenue for KNSA, versus a peer median of 61.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $34.81M | +48.0% | +209.8% | 38.5% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $30.52M | +87.1% | +191.0% | — |
| LTM Jun 2026 | $26.73M | +71.0% | +141.5% | 1404.0% | |
| LTM Sep 2026 | $20.29M | -13.4% | +49.5% | 285.9% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Jun 2026 | $13.22M | +35.1% | +110.3% | 1.6% | |
| LTM Mar 2026 | $11.74M | -40.2% | +21.4% | 5.1% | |
| LTM Mar 2026 | $6.99M | -14.1% | — | 83.5% | |
| LTM Mar 2026 | $4.38M | +27.1% | +211.0% | 1.2% | |
| LTM Mar 2026 | $4.01M | -8.1% | — | 6803.4% | |
| Peer median (excluding KNSA) | $18.56M | -8.1% | +141.5% | 61.0% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Cost of Revenue | 9.1M | 22.9M | 56.52M | 60.91M | 307.41M |
| Gross Profit | 29.44M | 197.29M | 213.74M | 362.33M | 370.15M |
| Gross Margin | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| Research & Development | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M |
| Selling, General & Admin | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Operating Expenses | 186.08M | 187.51M | 238.93M | 407.95M | 292.93M |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| EBITDA | (154.18M) | 13.43M | (14.31M) | (34.46M) | 90.42M |
| EBITDA Margin | -400.0% | 6.1% | -5.3% | -8.1% | 13.3% |
| Operating Income | (156.64M) | 9.77M | (25.2M) | (45.62M) | 77.22M |
| Operating Margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Interest Income | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Income Before Tax | (156.54M) | 11.03M | (16.65M) | (36.15M) | 88.87M |
| Pre-Tax Margin | -406.1% | 5.0% | -6.2% | -8.5% | 13.1% |
| Income Tax Expense | 1.39M | (172.34M) | (30.74M) | 7.04M | 29.86M |
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | 59.01M |
| Net Margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (Basic) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 |
| EPS (Diluted) | (2.30) | 2.60 | 0.20 | (0.60) | 0.75 |
| Weighted Avg Shares | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M |
| Weighted Avg Shares (Diluted) | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.